No Data
Vaccinex Announces Signing Of Proprietary Project Agreements With Amgen, Merck, Chugai, Absci, Gigagen, Merus, Soleil, ThirdArc And Incyte To Employ Vaccinex's ActivMAb Technology
HC Wainwright & Co. Reiterates Buy on Denali Therapeutics, Maintains $90 Price Target
Lululemon To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday
Arcellx Analyst Ratings
Acrellx Shares Are Trading Lower After the Company Announced That the Median Was Not Reached for Its Phase 1 Study of Anito-cel.
Alkermes Raised to Buy by Stifel on Increased Confidence for ALKS2680